Slingshot members are tracking this event:

PRM-151 (pentraxin-2) Advances into Phase 2 Stage for Myelofibrosis - Study to Complete in 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Bristol-Myers Squibb's recently acquired Promedior Inc. has advanced its lead therapeutic PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF) into Phase 2 clinical studies.  The ongoing Phase 2 trial is a multi-center, two stage, adaptive design study to determine the efficacy and safety of PRM-151 as a single agent or added to a stable dose of ruxolitinib in patients with various conditions of MF.  The study is expected to complete in 2017.
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Prm-151, Pentraxin-2, Phase 2 Trial, Myelofibrosis